These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
282 related articles for article (PubMed ID: 7775172)
1. Efficacy, safety, and tolerability of dihydroergotamine nasal spray as monotherapy in the treatment of acute migraine. Dihydroergotamine Nasal Spray Multicenter Investigators. Headache; 1995 Apr; 35(4):177-84. PubMed ID: 7775172 [TBL] [Abstract][Full Text] [Related]
2. Zolmitriptan 5 mg nasal spray: efficacy and onset of action in the acute treatment of migraine--results from phase 1 of the REALIZE Study. Gawel M; Aschoff J; May A; Charlesworth BR; Headache; 2005 Jan; 45(1):7-16. PubMed ID: 15663607 [TBL] [Abstract][Full Text] [Related]
3. A clinical comparison of sumatriptan nasal spray and dihydroergotamine nasal spray in the acute treatment of migraine. Boureau F; Kappos L; Schoenen J; Esperanca P; Ashford E Int J Clin Pract; 2000 Jun; 54(5):281-6. PubMed ID: 10954953 [TBL] [Abstract][Full Text] [Related]
4. Early intervention with almotriptan: results of the AEGIS trial (AXERT Early Migraine Intervention Study). Mathew NT; Finlayson G; Smith TR; Cady RK; Adelman J; Mao L; Wright P; Greenberg SJ; Headache; 2007 Feb; 47(2):189-98. PubMed ID: 17300358 [TBL] [Abstract][Full Text] [Related]
5. [Dihydroergotamine as a nasal spray in the therapy of migraine attacks. Efficacy and tolerance]. Jenzer G; Bremgartner MF Schweiz Rundsch Med Prax; 1990 Aug; 79(31-32):914-7. PubMed ID: 2203127 [TBL] [Abstract][Full Text] [Related]
6. A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine. Aurora SK; Rozen TD; Kori SH; Shrewsbury SB Headache; 2009 Jun; 49(6):826-37. PubMed ID: 19545249 [TBL] [Abstract][Full Text] [Related]
7. [Treatment of migraine attacks: combination of dihydroergotamine tartrate and paracetamol in comparison with individual drugs and placebo]. Hoernecke R; Doenicke A Med Klin (Munich); 1993 Nov; 88(11):642-8. PubMed ID: 8295604 [TBL] [Abstract][Full Text] [Related]
8. Zolmitriptan nasal spray exhibits good long-term safety and tolerability in migraine: results of the INDEX trial. Dowson AJ; Charlesworth BR; Green J; Färkkilä M; Diener HC; Hansen SB; Gawel M; Headache; 2005 Jan; 45(1):17-24. PubMed ID: 15663608 [TBL] [Abstract][Full Text] [Related]
9. Dihydroergotamine nasal spray for the acute treatment of migraine. Ziegler D; Ford R; Kriegler J; Gallagher RM; Peroutka S; Hammerstad J; Saper J; Hoffert M; Vogel B; Holtz N Neurology; 1994 Mar; 44(3 Pt 1):447-53. PubMed ID: 8145914 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of sumatriptan tablets in migraineurs self-described or physician-diagnosed as having sinus headache: a randomized, double-blind, placebo-controlled study. Ishkanian G; Blumenthal H; Webster CJ; Richardson MS; Ames M Clin Ther; 2007 Jan; 29(1):99-109. PubMed ID: 17379050 [TBL] [Abstract][Full Text] [Related]
12. Two replicate randomized, double-blind, placebo-controlled trials of the time to onset of pain relief in the acute treatment of migraine with a fast-disintegrating/rapid-release formulation of sumatriptan tablets. Sheftell FD; Dahlöf CG; Brandes JL; Agosti R; Jones MW; Barrett PS Clin Ther; 2005 Apr; 27(4):407-17. PubMed ID: 15922814 [TBL] [Abstract][Full Text] [Related]
13. Acute treatment of migraine with dihydroergotamine nasal spray. Dihydroergotamine Working Group. Gallagher RM Arch Neurol; 1996 Dec; 53(12):1285-91. PubMed ID: 8970458 [TBL] [Abstract][Full Text] [Related]
14. Oral sumatriptan for the acute treatment of probable migraine: first randomized, controlled study. Tepper SJ; Cady R; Dodick D; Freitag FG; Hutchinson SL; Twomey C; Kuhn TA Headache; 2006 Jan; 46(1):115-24. PubMed ID: 16412159 [TBL] [Abstract][Full Text] [Related]
15. Symptomatic relief of migraine: multicenter comparison of Cafergot P-B, Cafergot, and placebo. Friedman AP; Di Serio FJ; Hwang DS Clin Ther; 1989; 11(1):170-82. PubMed ID: 2497984 [TBL] [Abstract][Full Text] [Related]
16. Effect of pain intensity and time to administration on responsiveness to almotriptan: results from AXERT 12.5 mg Time Versus Intensity Migraine Study (AIMS). Freitag FG; Finlayson G; Rapoport AM; Elkind AH; Diamond ML; Unger JR; Fisher AC; Armstrong RB; Hulihan JF; Greenberg SJ; Headache; 2007 Apr; 47(4):519-30. PubMed ID: 17445101 [TBL] [Abstract][Full Text] [Related]
17. MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine. Aurora SK; Silberstein SD; Kori SH; Tepper SJ; Borland SW; Wang M; Dodick DW Headache; 2011 Apr; 51(4):507-17. PubMed ID: 21457235 [TBL] [Abstract][Full Text] [Related]
18. Dihydroergotamine: role in the treatment of migraine. Schürks M Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1141-8. PubMed ID: 19624283 [TBL] [Abstract][Full Text] [Related]
19. Valdecoxib for treatment of a single, acute, moderate to severe migraine headache. Kudrow D; Thomas HM; Ruoff G; Ishkanian G; Sands G; Le VH; Brown MT Headache; 2005 Oct; 45(9):1151-62. PubMed ID: 16178945 [TBL] [Abstract][Full Text] [Related]
20. Analgesic effects of intranasal butorphanol tartrate administered via a unit-dose device in the dental impaction pain model: a randomized, double-blind, placebo-controlled, parallel-group study. Wermeling DP; Grant GM; Lee A; Alexander N; Rudy AC Clin Ther; 2005 Apr; 27(4):430-40. PubMed ID: 15922816 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]